Whitehawk Therapeutics Inc carries no debt; cash flow comfortably covers obligations.

Whitehawk Therapeutics Inc's free cash flow has decreased 60.10% from $-61.20M last year to $-97.98M, signaling decreasing performance

Whitehawk Therapeutics Inc's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Whitehawk Therapeutics Inc's debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials

Whitehawk Therapeutics Inc has a net cash position, so leverage is healthy.

Whitehawk Therapeutics Inc earns at least as much interest as it pays. Interest obligations are fully covered.

Whitehawk Therapeutics Inc's profit margin has increased (-100.00%) in the last year from -245.13% to 0.00%, signaling increasing performance

Whitehawk Therapeutics Inc's short-term assets of $149.01M exceed its short-term liabilities of $14.52M

Whitehawk Therapeutics Inc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Whitehawk Therapeutics Inc's return on equity of -53.89%, is lower than 15.00%, indicating bad performance

Whitehawk Therapeutics Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Whitehawk Therapeutics Inc had positive net income in only 0 out of 5 years, indicating unstable earnings

Whitehawk Therapeutics Inc has negative free cash flow, indicating the company is burning cash rather than generating it

Whitehawk Therapeutics Inc has negative free cash flow, indicating cash burn

Whitehawk Therapeutics Inc's yearly earnings has increased -67.66% since last year from $-63.69M to $-20.60M, signaling increasing performance

Whitehawk Therapeutics Inc's yearly revenue has decreased 72.50% since last year from $25.98M to $7.14M, signaling decreasing performance

ROIC -47.05% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Whitehawk Therapeutics Inc's 3-year revenue CAGR of -22.27% is negative, indicating declining revenue over the past 3 years

Whitehawk Therapeutics Inc had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Whitehawk Therapeutics Inc had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Whitehawk Therapeutics Inc has insufficient data to evaluate this check.

Whitehawk Therapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Whitehawk Therapeutics Inc is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Whitehawk Therapeutics Inc has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Whitehawk Therapeutics Inc is overvalued relative to its fair value price of -3.19 based on Earnings Fair Value model

Whitehawk Therapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Whitehawk Therapeutics Inc has a price-to-book ratio of 2.06x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Whitehawk Therapeutics Inc has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue